Skip to content
Clinical Trials – home
Centre Hospitalier Universitaire De Montpellier
Sponsor

Centre Hospitalier Universitaire De Montpellier

France 39 Avenue Charles Flahault, 34295 Montpellier, France

About the sponsor

Rheumatoid arthritis research includes treatment strategies for persistent inflammatory disease, with interest in biologic sequencing and disease control. Systemic sclerosis is also a focus, including severe, treatment-resistant forms associated with skin fibrosis and immune-mediated tissue damage.

  • Rheumatoid arthritis
  • Systemic sclerosis
  • Autoimmune disease

Work in this area reflects a strong interest in immune modulation, refractory disease, and outcomes linked to inflammatory activity.

About Specializations

Centre Hospitalier Universitaire De Montpellier runs clinical trials in conditions such as Hepatocellular carcinoma, Neurodevelopmental disorder, Relapsing-remitting multiple sclerosis, Cholangiocarcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

20 clinical trials

Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carbidopa
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin Dihydrate
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dexmedetomidine
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Midazolam
  • Sponsor:Centre Hospitalier Universitaire De Montpellier
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daridorexant
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Cardiac failure

Not yet recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetazolamide
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Restless legs syndrome

Not yet recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Carboxymaltose
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).